Celyad Oncology SA
XBRU:CYAD

Watchlist Manager

Celyad Oncology SA

XBRU:CYAD

Watchlist

Dividends

Price: 0.4745 EUR -5.1% Market Closed

Market Cap: 19.7m EUR

Have any thoughts about
Celyad Oncology SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 0.4745 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

CYAD Alert

Celyad Oncology SA

0.4745

-0.0255 (-5.1%)

52 Week Range	0.2295 1
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Celyad Oncology SA

What unique competitive advantages
does Celyad Oncology SA hold over its rivals?

What risks and challenges
does Celyad Oncology SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Celyad Oncology SA.

What unique competitive advantages
does Celyad Oncology SA hold over its rivals?

What risks and challenges
does Celyad Oncology SA face in the near future?

Summarize the latest earnings call
of Celyad Oncology SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Celyad Oncology SA.

Provide P/S
for Celyad Oncology SA.

Provide P/E
for Celyad Oncology SA.

Provide P/OCF
for Celyad Oncology SA.

Provide P/FCFE
for Celyad Oncology SA.

Provide P/B
for Celyad Oncology SA.

Provide EV/S
for Celyad Oncology SA.

Provide EV/GP
for Celyad Oncology SA.

Provide EV/EBITDA
for Celyad Oncology SA.

Provide EV/EBIT
for Celyad Oncology SA.

Provide EV/OCF
for Celyad Oncology SA.

Provide EV/FCFF
for Celyad Oncology SA.

Provide EV/IC
for Celyad Oncology SA.

Show me price targets
for Celyad Oncology SA made by professional analysts.

What are the Revenue projections
for Celyad Oncology SA?

How accurate were the past Revenue estimates
for Celyad Oncology SA?

What are the Net Income projections
for Celyad Oncology SA?

How accurate were the past Net Income estimates
for Celyad Oncology SA?

What are the EPS projections
for Celyad Oncology SA?

How accurate were the past EPS estimates
for Celyad Oncology SA?

What are the EBIT projections
for Celyad Oncology SA?

How accurate were the past EBIT estimates
for Celyad Oncology SA?

Compare the revenue forecasts
for Celyad Oncology SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Celyad Oncology SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Celyad Oncology SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Celyad Oncology SA compared to its peers.

Compare the P/E ratios
of Celyad Oncology SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Celyad Oncology SA with its peers.

Analyze the financial leverage
of Celyad Oncology SA compared to its main competitors.

Show all profitability ratios
for Celyad Oncology SA.

Provide ROE
for Celyad Oncology SA.

Provide ROA
for Celyad Oncology SA.

Provide ROIC
for Celyad Oncology SA.

Provide ROCE
for Celyad Oncology SA.

Provide Gross Margin
for Celyad Oncology SA.

Provide Operating Margin
for Celyad Oncology SA.

Provide Net Margin
for Celyad Oncology SA.

Provide FCF Margin
for Celyad Oncology SA.

Show all solvency ratios
for Celyad Oncology SA.

Provide D/E Ratio
for Celyad Oncology SA.

Provide D/A Ratio
for Celyad Oncology SA.

Provide Interest Coverage Ratio
for Celyad Oncology SA.

Provide Altman Z-Score Ratio
for Celyad Oncology SA.

Provide Quick Ratio
for Celyad Oncology SA.

Provide Current Ratio
for Celyad Oncology SA.

Provide Cash Ratio
for Celyad Oncology SA.

What is the historical Revenue growth
over the last 5 years for Celyad Oncology SA?

What is the historical Net Income growth
over the last 5 years for Celyad Oncology SA?

What is the current Free Cash Flow
of Celyad Oncology SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Celyad Oncology SA.

P/FCFE
Price to FCFE

-1.9

Current

-1

Median

27.3

Industry

Lower than median

Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE

-1.9

Market Cap

19.7m EUR

FCFE

-10.5m EUR

All Countries

Forward Multiples

			Market Cap	P/FCFE
BE		Celyad Oncology SA XBRU:CYAD	19.7m EUR	-1.9
FR		Pharnext SCA OTC:PNEXF	6T USD	-3 183 345.6
US		Abbvie Inc NYSE:ABBV	300.2B USD	12.1
US		Amgen Inc NASDAQ:AMGN	159.1B USD	26.7
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	126.6B USD	-91.5
US		Gilead Sciences Inc NASDAQ:GILD	114.6B USD	11.4
US	E	Epizyme Inc F:EPE	94.1B EUR	-431
AU		CSL Ltd ASX:CSL	137.3B AUD	80.9
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	87.6B USD	26.5
US	S	Seagen Inc F:SGT	39.3B EUR	-59.3
NL		argenx SE XBRU:ARGX	34.1B EUR	-108.8


BE		Celyad Oncology SA XBRU:CYAD	Average P/FCFE: 31.5 Negative Multiple: -1.9
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -3 183 345.6
US		Abbvie Inc NYSE:ABBV	12.1
US		Amgen Inc NASDAQ:AMGN	26.7
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	Negative Multiple: -91.5
US		Gilead Sciences Inc NASDAQ:GILD	11.4
US	E	Epizyme Inc F:EPE	Negative Multiple: -431
AU		CSL Ltd ASX:CSL	80.9
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	26.5
US	S	Seagen Inc F:SGT	Negative Multiple: -59.3
NL		argenx SE XBRU:ARGX	Negative Multiple: -108.8

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

P/FCFE

N/A

2-Years Forward

P/FCFE

N/A

3-Years Forward

P/FCFE

N/A

Celyad Oncology SA
XBRU:CYAD

P/FCFE
Price to FCFE

P/FCFE Forward Multiples

See Also

Company

Help

Tools

Stocks

Celyad Oncology SA XBRU:CYAD

P/FCFE Price to FCFE

P/FCFE Forward Multiples

See Also

Company

Help

Tools

Stocks

Celyad Oncology SA
XBRU:CYAD

P/FCFE
Price to FCFE